New synthetic tetrapeptide launched by Chemyunion to target pigmentation
Last update on Jun 1, 2026
Hyperpigmentation is one of the leading dermatological concerns worldwide. However, many conventional skin-lightening agents act aggressively on melanogenesis. This type of treatment may trigger a cycle of irritation and mild inflammation. As a result, the rebound effect may occur. In this case, the skin reacts by producing more melanin as a defense mechanism.
To develop safer and more effective formulations, cosmetic science has been seeking more sophisticated strategies based on the intelligent modulation of cellular receptors and the epigenetic regulation of pigmentation.
In response to this challenge, Chemyunion developed Peptid4® Light MB (INCI: Palmitoyl Tetrapeptide-112), a synthetic tetrapeptide created through rational in-silico molecular design.
View Chemyunion's full product range directly in the Master Catalog of Cosmetics
Interrupts melanogenesis signaling cascade before pigment formation occurs
The pursuit of even and healthy skin is undergoing a scientific transformation. The global skincare market is no longer limited to treating visible signs of aging. It is evolving toward understanding and modulating biological mechanisms that affect skin health over time.
In this context, epigenetic longevity emerges as one of the leading trends for 2026–2027 in the development of high-performance cosmetic ingredients. This scientific approach is based on the ability to modulate the skin's gene expression. It influences processes such as inflammation, melanin production, and cellular regeneration without altering the DNA sequence.
For brands and formulators, this marks a paradigm shift. Instead of treating only already-formed dark spots, cosmetic innovation now acts at the origin of the problem. It addresses the biological mechanisms associated with hyperpigmentation, with the aim of promoting longer-lasting results that are more compatible with skin physiology.
According to Chemyunion, the ingredient acts directly on the melanocortin-1 receptor (MC1R), considered one of the key regulators of cutaneous melanogenesis.
Unlike traditional depigmenting agents, Peptid4® Light MB acts as a high-affinity competitive antagonist. It occupies the receptor before inflammatory stimuli activate the melanin production cascade.
Key mechanisms of action, as described by the supplier:
Action at the origin of pigmentation: Interrupts the melanogenesis signaling cascade before pigment formation occurs.
- Modulation of cutaneous inflammation: Reduces inflammatory mediators associated with post-inflammatory hyperpigmentation.
- Well-aging approach: Promotes more balanced and even-toned skin by modulating cellular responses related to aging.
Seeking anti-aging agents from Chemyunion? See grades here!
Scientifically proven results
Efficacy data reported by Chemyunion: The efficacy of Peptid4® Light MB was evaluated in ex vivo and clinical studies. Advanced technologies were used to analyze skin imaging and biomarkers. Among the results reported:
- 66% reduction in total melanin content compared to placebo
- 63% increase in type I collagen synthesis, contributing to improved skin firmness
- Visible improvement in skin tone uniformity within 28 days, evaluated through advanced dermatological imaging systems
The supplier indicates that these findings demonstrate that intelligent modulation of pigmentation can deliver combined benefits of tone uniformity and structural skin improvement.
Aligned with demands for clean beauty
Chemyunion reports that Peptid4® Light MB meets the following sustainability criteria, aligned with global demands for clean beauty and responsible innovation:
- 99% natural origin (ISO 16128)
- Vegan ingredient
- Developed under Green Chemistry principles
Suitable for daytime use, with no reported photosensitivity
This combination may support the development of formulations compatible with consumer expectations for transparency and reduced environmental impact.
The trend of epigenetic longevity in skincare represents a measurable evolution in cosmetic ingredient development. By targeting cellular mechanisms related to aging and pigmentation, this approach enables treatments that are more longer-lasting and more compatible with skin biology.
With Peptid4® Light MB, Chemyunion introduces an ingredient offering a solution capable of modulating melanogenesis with molecular precision, promoting skin that is more even, healthy, and resilient over time.